Reaktion #1726712

ord-e18c9eaa04fa475abf3e7ca4c3afc891

Reaktionsgleichung

O=C1CCNCC1
4-piperidone
NC(=O)c1cc2ccccc2cc1O
3-hydroxy-2-naphthalenecarboxamide
C1COCCN1
morpholine
O=C1NC2(CCNCC2)Oc2cc3ccccc3cc21
Compound 159
O=C1NC2(CCNCC2)Oc2cc3ccccc3cc21
spiro[2H-naphtho[2,3-e]-1,3-oxazin-2,4′-piperidin]-4-(3H)-one

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Aufarbeitung

  1. 1
    Temperaturis refluxed for 20 hr
  2. 2
    Waschenwashed with water, brine
  3. 3
    Trocknendried over Na2SO4
  4. 4
    SonstigeAfter solvent removal by rotoevaporation
  5. 5
    Sonstigethe crude product is purified by preparative TLC

Vorschrift

A mixture of 26 mg (0.083 mmol) of N-[4,8-dimethoxyquinoline-2-yl)carbonyl]-4-piperidone (prepared as described in Example 44), 15.5 mg (0.083 mmol) of 3-hydroxy-2-naphthalenecarboxamide, and 0.020 mL of morpholine in a mixture of 0.2 mL of toluene and 0.6 mL of methanol is refluxed for 20 hr. The reaction mixture is diluted with ethyl acetate, and washed with water, brine, and dried over Na2SO4. After solvent removal by rotoevaporation, the crude product is purified by preparative TLC to give 11 mg (0.023 mmol, 27% yield) of 1′-[4,8-dimethoxyquinoline-2-yl)carbonyl]spiro[2H-naphtho[2,3-e]-1,3-oxazin-2,4′-piperidin]-4-(3H)-one (Compound 159): 1H NMR (DMSO-d6): δ 3.95 (s, 3H), 4.07 (s, 3H), 7.20 (s, 1H), 7.23 (d, 1H), 7.44 (d of d, 1H), 7.55 (m, 3H), 7.67 (d, 1H), 8.04 (d, 1H), 8.46 (s, 1H), and 9.09 ppm (s, 1H). MS m/z: 484.0 (M+H)+, 506.0 (M+Na)+.

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US08110570B2uspto-grants-2012_02